Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review

Pancreatic ductal adenocarcinoma (PDAC), a highly aggressive malignancy with a poor prognosis is usually detected at the advanced stage of the disease. The only US Food and Drug Administration-approved biomarker that is available for PDAC, CA 19-9, is most useful in monitoring treatment response amo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vellan, Christina Jane, Jayapalan, Jaime Jacqueline, Yoong, Boon-Koon, Abdul-Aziz, Azlina, Mat-Junit, Sarni, Subramanian, Perumal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879036/
https://www.ncbi.nlm.nih.gov/pubmed/35216204
http://dx.doi.org/10.3390/ijms23042093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879036/
https://www.ncbi.nlm.nih.gov/pubmed/35216204
http://dx.doi.org/10.3390/ijms23042093

Ejemplares similares